drugset / Trial / NCT03088176
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine safety and tolerability of the combination of talimogene laherparepvec in combination with dabrafenib and trametinib in BRAF mutated advanced melanoma.
Timeline
- Start
- 2017-06-25
- Primary completion
- 2020-11-30
- Completion
- 2021-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | 150 mg | Oral |
| Subject | Talimogene Laherparepvec | Other / unclassified | 4 ml | Other |
| Subject | Trametinib | Small molecule | 2 mg | Oral |